Switch View
© BusinessWire
03.11.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
News Preview
Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.
The lawsuit asserts that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action by Novo Nordisk to protect its...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: CA71719L1067
Pharmala Biotech Holdings Inc.
MDMA
LISTED
CSE
PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
News Preview
PharmAla files its final short form prospectus, and announces a signed term sheet with an R&D tax credit financing firm called Radium...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US31447E1055
Femasys Inc
FEMY
LISTED
NASDAQ
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
News Preview
-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys’ wo...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
03.11.2025
ISIN: AU000000AVH4
Avita Medical Inc.
AVH
LISTED
ASX
Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment
News Preview
AVITA Medical data at SRBC 2025 confirms RECELL® as standard of care, improving healing, reducing hospital stays, and lowering treatment costs...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
03.11.2025
ISIN: US0044685008
Achieve Life Sciences, Inc.
ACHV
LISTED
NASDAQ
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
News Preview
120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US46266A1097
IRadimed Corp
IRMD
LISTED
NASDAQ
IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results
News Preview
Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US1374041093
Candel Therapeutics, Inc.
CADL
LISTED
NASDAQ
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
News Preview
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US14888U1016
Catalyst Pharmaceuticals Inc
CPRX
LISTED
NASDAQ
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
News Preview
CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, Presiden...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US74168J1016
Prime Medicine Inc
PRME
LISTED
NASDAQ
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
News Preview
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Prime’s corporate and...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: CA60255C8850
Mind Medicine (MindMed) Inc
MNMD
LISTED
NASDAQ
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing of its previously announced underwritten public offering of 21,131,250 common shares, without par value, which includes the exerci...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US92790C1045
Viridian Therapeutics Inc
VRDN
LISTED
NASDAQ
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
News Preview
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced the successful October submission of its BLA to the U.S. Food and Drug Administration (FDA) for veligrotug, the company’s investigational ther...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US63909J1088
Nautilus Biotechnology Inc
NAUT
LISTED
NASDAQ
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
News Preview
• Buck Institute’s deployment of Nautilus’ instrument generates tau proteoform data, providing external validation of the company’s next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a fundamental shift in how proteomics technology can adv...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
03.11.2025
ISIN: IL0011316309
Mediwound Ltd
MDWD
LISTED
NASDAQ
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
News Preview
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US53635D2027
Liquidia Corp
LQDA
LISTED
NASDAQ
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
News Preview
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing updates on the company's business during fireside chat...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: ES0167733015
Oryzon Genomics SA
ORY
LISTED
BME
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
News Preview
MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics, today announced that the first patient has been enrolled in RESTORE, its multi‑center, open‑label Phase Ib clinical trial of iadademstat in adults...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US8693671021
Sutro Biopharma Inc
STRO
LISTED
NASDAQ
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC Conference, taking place in San Diego, November 3-6, 2025....
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US1167941087
Bruker Corp
BRKR
LISTED
NASDAQ
Bruker Reports Third Quarter 2025 Financial Results
News Preview
Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and nine months ended September 30, 2025.
Frank H. Laukien, Bruker’s President and CEO, commented: “In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bil...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US91307C1027
United Therapeutics Corp
UTHR
LISTED
NASDAQ
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
News Preview
United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its EXPAND study of the UKidney™ in patients with end-stage renal disease (ESRD). The successful transplant operation was performed at NYU Langone Health.
United Therapeutics’ UKidney is an investigational xenokidney from a pig with 10 gene e...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US74766Q1013
Quanterix Corp
QTRX
LISTED
NASDAQ
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m. E.T., to discuss its third quarter 2025 financial results.
Quanterix will issue a press release regarding its third quarter 2025 fi...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US4834971032
Kalvista Pharmaceuticals Inc
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company’s third quarter financial results and provide an operational update.
The live audio webcast will be accessible on the Investors section of the Company’s website at www.ir.kalvista.com/event-ca...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US3773221029
Glaukos Corp
GKOS
LISTED
NYSE
Glaukos Announces Participation in Upcoming Investor Conferences
News Preview
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:
UBS Global Healthcare Conference on Tuesda...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US7133171055
PepGen Inc
PEPG
LISTED
NASDAQ
PepGen to Participate in Upcoming Investor Conferences
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:
Guggenheim Securities 2nd An...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its cardiovascular portfolio at the American Heart Association’s Scientific Sessions 2025, taking place November 7–10, 2025 in New Orleans, Louisiana. New analyses include results from a long-term extension study and real-world evidence that reinforce how Camzyos (mavac...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
News Preview
The Merck Foundation announced today the launch of the Collaborative for Equity in Cardiac Care, a $22 million, five-year initiative aimed at enhancing access to high-quality, person-centered health care for people living with heart conditions in the U.S. Eleven organizations are receiving grants to support the development and implementation of ev...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
News Preview
Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
News Preview
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orle...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
News Preview
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of Nephrology’s (ASN) annual meeting, taking place November 5-9 in Houston, Texas. Felzartamab, an investigational anti-CD38 monoclonal antibody, is cur...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US45779A8466
InspireMD, Inc.
NSPR
LISTED
NASDAQ
InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer
News Preview
MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US03770N1019
Apogee Therapeutics Inc
APGE
LISTED
NASDAQ
Apogee Therapeutics to Participate in Upcoming Conferences
News Preview
SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US26818M1080
Dyne Therapeutics Inc
DYN
LISTED
NASDAQ
Dyne Therapeutics to Present at Upcoming Investor Conferences
News Preview
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US00887A2042
Rein Therapeutics Inc
ALRN
LISTED
NASDAQ
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
News Preview
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US3441741077
Foghorn Therapeutics Inc
FHTX
LISTED
NASDAQ
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
News Preview
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Confere...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US45168D1046
IDEXX Laboratories, Inc.
IDXX
LISTED
NASDAQ
IDEXX Laboratories Announces Third Quarter Results
News Preview
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results.
Third Quarter Results
The Company reports revenues of $1,105 million for the third quarter of 2025, an increase of 13% as reported and 12% organic, driven by Companion Animal Group ("CAG") growth of 14% as reported and...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US8064071025
Henry Schein Inc
HSIC
LISTED
NASDAQ
Henry Schein One and AWS Collaborate to Transform Global Dentistry with Generative AI
News Preview
Henry Schein One, a leading global provider of dental technology, today announced a groundbreaking partnership with Amazon Web Services (AWS), the world’s most comprehensive and broadly adopted cloud platform. Together, the companies will integrate AWS’s generative AI (GenAI) technologies across the Henry Schein One platform — including Dentrix, D...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US8688731004
Surmodics Inc
SRDX
LISTED
NASDAQ
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
News Preview
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Sean Lyden, Dr. Joseph Campbell, and Dr. Peter Monteleone, will present and discuss updated safety and performance data from the PROWL registry on 160 patients with symptomatic lower extrem...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US08205P1003
Benitec Biopharma, Inc.
BNTC
LISTED
NASDAQ
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
News Preview
HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today provides positive interim clinic...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: NL0010696654
Uniqure NV
QURE
LISTED
NASDAQ
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
News Preview
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA)...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US5011471027
Krystal Biotech Inc
KRYS
LISTED
NASDAQ
Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results
News Preview
$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US05464T1043
Axsome Therapeutics Inc
AXSM
LISTED
NASDAQ
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US7473241013
Pyxis Oncology Inc
PYXS
LISTED
NASDAQ
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US88322Q1085
TG Therapeutics Inc
TGTX
LISTED
NASDAQ
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
News Preview
Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US09058V1035
BioCryst Pharmaceuticals Inc
BCRX
LISTED
NASDAQ
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US5015751044
Kymera Therapeutics Inc
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
News Preview
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences to Participate in Upcoming Conferences
News Preview
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US1420381089
Caribou Biosciences Inc
CRBU
LISTED
NASDAQ
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
News Preview
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinical data from dose escalation in the ongoing CaMMouflage phase 1 trial evaluating CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, in relapsed...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US61225M1027
Monte Rosa Therapeutics Inc
GLUE
LISTED
NASDAQ
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
News Preview
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US58502B1061
Pediatrix Medical Group Inc
MD
LISTED
NYSE
Pediatrix Medical Group Reports Third Quarter Results
News Preview
Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.84 per share for the three months ended September 30, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.67.
For the 2025 third quarter, Pediatrix reported the following results:
Net revenue of $493 million;
Net i...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: CA05156V1022
Aurinia Pharmaceuticals Inc
AUPH
LISTED
NASDAQ
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
News Preview
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025.
Aurinia’s management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the we...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US09075V1026
Biontech SE
BNTX
LISTED
NASDAQ
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
News Preview
BioNTech SE today reported financial results for the three and nine months ended September 30, 2025 and provide an update on its corporate progress....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: CA72706K1012
Planet 13 Holdings Inc.
PLTH
LISTED
CSE
Planet 13 Streamlines Footprint to Focus on Core Growth Markets
News Preview
Planet 13 Divests Non-Core Orange County Store and Closes Coalinga Cultivation Facility Planet 13 Divests Non-Core Orange County Store and Closes Coalinga Cultivation Facility...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US89854M1018
TScan Therapeutics, Inc.
TCRX
LISTED
NASDAQ
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
News Preview
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US53635D2027
Liquidia Corp
LQDA
LISTED
NASDAQ
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also ho...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US29358P1012
Ensign Group Inc
ENSG
LISTED
NASDAQ
The Ensign Group Expands in Utah
News Preview
SAN JUAN CAPISTRANO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced to...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US29358P1012
Ensign Group Inc
ENSG
LISTED
NASDAQ
The Ensign Group Adds Operation in Alabama
News Preview
SAN JUAN CAPISTRANO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced to...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: SE0002190926
Karolinska Development AB
KDEV
LISTED
STO
Karolinska Development’s portfolio company BOOST Pharma raises SEK 34 million through directed share issue to Sound Bioventures
News Preview
Stockholm, Sweden – November 3, 2025 – Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has raised a SEK 34 million investment structured as a tranched convertible loan from Sound Bioventures.The investment supports continued clinical development of BT-101, a pioneering stem cell-based thera...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
News Preview
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb” or the “Offeror”), announced the commencement of tender offers (“Offers”) to purchase for cash certain of its outstanding notes (collectively, the “Notes”) as described in the tables below.
Pool 1
Offers to purchase for cash up to $4,000,000,000 aggregate purchase price for the sec...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH Investors Have Opportunity to Lead Molina Healthcare, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Molina Healthcare, Inc. ("Molina" or "the Company") (NYSE: MOH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MOH
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Molina Healthcare, Inc. ("Molina " or "the Company") (NYSE: MOH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US80303D3052
SANUWAVE Health, Inc.
SNWV
LISTED
NASDAQ
CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)
News Preview
CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.11.2025
ISIN: DE000A1MMCC8
Medios AG
ILM1
LISTED
XETR
Thomas Meier becomes new CEO of Medios AG
News Preview
Press release
Thomas Meier becomes new CEO of Medios AG
Berlin, November 3, 2025 – The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and designated him the new Chief Executive Officer (CEO) of the Company. He succeeds Matthias Gaertner, who will remain in office un......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
